Prana Biotechnology Limited Company Profile (ASX:PBT)

About Prana Biotechnology Limited (ASX:PBT)

Prana Biotechnology Limited logoPrana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: ASX:PBT
  • CUSIP: N/A
  • Web:
  • Trailing P/E Ratio:
  • P/E Growth:
  • Dividend Yield: 1.0%
  • Net Margins: -5,010.77%
  • Return on Equity: -24.72%
  • Return on Assets: -22.71%
Frequently Asked Questions for Prana Biotechnology Limited (ASX:PBT)

What is Prana Biotechnology Limited's stock symbol?

Prana Biotechnology Limited trades on the ASX under the ticker symbol "PBT."

Who are some of Prana Biotechnology Limited's key competitors?

Who are Prana Biotechnology Limited's key executives?

Prana Biotechnology Limited's management team includes the folowing people:

  • Geoffrey Paul Kempler, Executive Chairman of the Board, Chief Executive Officer
  • Kathryn Andrews, Chief Financial Officer
  • Dianne Angus, Chief Operating Officer
  • Phillip Hains, Company Secretary
  • Ira Shoulson, Non-Executive Director
  • Lawrence Gozlan, Non-Executive Independent Director
  • Peter Ashley Marks, Non-Executive Independent Director
  • Brian Derek Meltzer, Non-Executive Independent Director
  • George William Mihaly, Non-Executive Independent Director

MarketBeat Community Rating for Prana Biotechnology Limited (ASX PBT)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  4 (Vote Outperform)
Underperform Votes:  5 (Vote Underperform)
Total Votes:  9
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Prana Biotechnology Limited (ASX:PBT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Prana Biotechnology Limited (ASX:PBT)
No equities research coverage for this company has been tracked by


Earnings History for Prana Biotechnology Limited (ASX:PBT)
No earnings announcements for this company have been tracked by


Earnings Estimates for Prana Biotechnology Limited (ASX:PBT)

No earnings estimates for this company have been tracked by


Dividend History for Prana Biotechnology Limited (ASX:PBT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Prana Biotechnology Limited (ASX:PBT)
No insider trades for this company have been tracked by


Headline Trends for Prana Biotechnology Limited (ASX:PBT)
Latest Headlines for Prana Biotechnology Limited (ASX:PBT)
DateHeadline logoPrana Biotechnology Get Back To Nasdaq's Continued Listings - April 11 at 10:17 AM


Social activity is not available for this stock.
This page was last updated on 7/27/2017 by Staff